Evidence map›Paper›PMID 42543261›Full record

ArticleSignal transduction and targeted therapy2026

BCL9 inhibition promotes fibroblast lipogenesis by regulating macrophage-fibroblast interactions to attenuate pulmonary fibrosis.

Wenjie Wang, Yuan Zhang, Fenglian He, Li Sun, Huiyu Li, Rongchen Liu, Guanglin Zhong, Ling Zhang, Anqi Li, Mei Feng and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Wenjie Wang *Institute of Clinical Medicine, Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuan Zhang *Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Fenglian He *The Postdoctoral Innovation and Practice Base, The Second Affiliated Hospital of Guilin Medical University, Guilin, China.
Li Sun *State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Huiyu Li *Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Rongchen LiuState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Guanglin ZhongSchool of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Ling ZhangDepartment of Pulmonology, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China.
Anqi LiDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China.
Mei FengDepartment of Pharmacology, School of Basic Medical Science, Fudan University, Shanghai, China.
Yuxuan DongDepartment of Pharmacology, School of Basic Medical Science, Fudan University, Shanghai, China.
Xiaoxuan LuDepartment of Pharmacology, School of Basic Medical Science, Fudan University, Shanghai, China.
Xiaojin WangInstitute of Clinical Medicine, Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuan SiState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yejun WuInstitute of Clinical Medicine, Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Mengmeng ZhaoDepartment of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Dafu ZhuDepartment of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID http://orcid.org/0000-0001-8301-7999
Zhuyi XiState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jian ChenKey Laboratory of Tumor Immunology and Microenvironmental Regulation of Guangxi, Guilin Medical University, Guilin, Guangxi, China.
Jing ChenState Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Ming-Wei WangDepartment of Pharmacology, School of Basic Medical Science, Fudan University, Shanghai, China. mwwang@simm.ac.cn.ORCID http://orcid.org/0000-0001-6550-9017
Di ZhuDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China. zhudi@fudan.edu.cn.ORCID http://orcid.org/0000-0003-4622-4600
Likun GongDepartment of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China. lkgong@simm.ac.cn.ORCID http://orcid.org/0000-0002-1896-4188
Bingshun WangInstitute of Clinical Medicine, Ruijin Hospital Luwan Branch, Shanghai Jiao Tong University School of Medicine, Shanghai, China. wangbingshun@sjtu.edu.cn.ORCID http://orcid.org/0000-0002-0435-2543

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease with an urgent need for novel therapeutic strategies. M2 macrophage-derived TGF-β1 promotes fibroblast myogenesis, contributing to IPF pathogenesis. Targeting macrophage polarization and fibroblast function thus represents an effective therapeutic approach for treating IPF. Here, we identify B-cell lymphoma 9 (BCL9) as a key upstream regulator implicated in IPF pathogenesis. We demonstrate that BCL9 drives the macrophage M2 program through the MerTK-ERK-SPP1 axis. Notably, pharmacological inhibition of BCL9 with our novel peptide, hsBCL9

Indexed as

FibroblastsIdiopathic Pulmonary FibrosisLipogenesisMacrophagesTranscription FactorsAnimalsCell CommunicationHumansMiceTransforming Growth Factor beta1BCL9 protein, humanTranscription FactorsTransforming Growth Factor beta1

Identifiers

PMID42543261
PMCPMC13429621

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.